Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 20, 2010
Event Date: January 19, 2010
Context: The filing discloses a material development regarding the Company's clinical trial progress under Regulation FD.
Key Financial Metrics
This filing is a current report regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Clinical Milestone: The Company announced the completion of patient enrollment in its Phase 2B clinical study for ORMD-0801, an oral insulin capsule.
- Location: The study is being conducted in South Africa.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) detailing the enrollment completion but does not include specific forward-looking guidance, financial outlook, or detailed risk factors within the body of this 8-K text.
Key Facts for Investor Verification
- Verify the full text of the press release dated January 19, 2010 (Exhibit 99.1) for details on the Phase 2B study design and next steps.
- Confirm the timeline for the completion of the Phase 2B study and the anticipated release of data.
- Review the Company's most recent 10-K or 10-Q filings for current financial status, as this 8-K contains no financial data.